mephentermine sulfate
Trade name: wyamine sulfate
Approved
Dec 29, 1951
Mephentermine, an amphetamine-derived phenethylamine, is an alpha 1 adrenergic receptor agonist and a hypertensive drug. Mephentermine is mainly used as a vasopressor agent with a sympathomimetic action, primarily causing release of noradrenaline and increasing cardiac output due to positive inotropic effect on the myocardium. The injectable preparation of mephentermine is commonly used for the short-term treatment of various hypotensive states such as shock or hypotension accompanying myocardial infarction or spinal anesthesia or surgical procedures like cesarean section. There is evidence on the fetal metabolic effect and placental transfer of mephentermine. However, a few studies have shown that mephentermine is as effective as phenylephrine in preventing maternal hypotension after spinal anesthesia and has similar effect on neonatal outcome. It is being widely used in developing countries like India as it is much more economical than phenylephrine and offers ease of use as it does not necessitate multiple dilutions as injectable. It is also available in India as 10 mg oral tablets. Despite it was thought earlier to have a little stimulant effect its abuse potential has increased, especially in sports due to its stimulant properties. Like amphetamines, it has shown to increase athletic performance in strength exercises and endurance in a dose of 14 mg/70 kg body weight. It has been proposed that phentermine, which is the main metabolite of mephentermine, acts by inhibiting monoaminoxidases A and B. Mephentermine adverse effects has been related to CNS simulation, excessive rises in blood pressure, and arrhythmias. Wyamine Sulfate (brand name of mephentermine sulfate) approved by FDA in 1951 was discontinued in USA. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 2 marketing orgs
Earliest trial started Mar 23, 2023 (NCT05706727)
Timeline
1950s
- Dec 29, 1951
American Home Products — Earliest FDA Approval
- Dec 29, 1951
Baxalta — Marketing Organization
- Dec 29, 1951
American Home Products — NDA Organization
- Dec 29, 1951
Baxalta — NDA Secondary Org
2020s
- Jan 1, 2023
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- Adrenergic receptorAGONIST
Adrenergic receptor agonist
- Alpha-1A adrenergic receptor (ADRA1A) ↗
- Alpha-2A adrenergic receptor (ADRA2A) ↗
- Beta-1 adrenergic receptor (ADRB1) ↗
- Beta-2 adrenergic receptor (ADRB2) ↗
- Alpha-2C adrenergic receptor (ADRA2C) ↗
- Alpha-1D adrenergic receptor (ADRA1D) ↗
- Alpha-1B adrenergic receptor (ADRA1B) ↗
- Alpha-2B adrenergic receptor (ADRA2B) ↗
- Beta-3 adrenergic receptor (ADRB3) ↗
- Beta-2 adrenergic receptor
- Beta-1 adrenergic receptor
- Alpha-2a adrenergic receptor
- Alpha-1d adrenergic receptor
- Alpha-1a adrenergic receptor
- Alpha-1b adrenergic receptor
- Alpha-2b adrenergic receptor
- Alpha-2c adrenergic receptor
- Beta-3 adrenergic receptor
- Adrenergic receptor beta
- Adrenergic receptor alpha-1
- Adrenergic receptor alpha-2
- Adrenergic receptor alpha
- Adrenergic receptors; alpha-1 A & B
- Adrenergic receptor beta; ADRB1 & ADRB2
- Adrenergic receptor beta; ADRB1 & ADRB3
- Alpha adrenergic receptor (1a and 1d)
- Beta-2 adrenergic receptor and beta-3 adrenergic receptor
Approval history
- approvedDec 29, 1951
Chemistry & pharmacology
SMILES
CNC(C)(C)Cc1ccccc1.CNC(C)(C)Cc1ccccc1.O=S(=O)(O)O- Mol. weight
- 424.61 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL3184799 ↗
- WikipediaMephentermine ↗
- NCATSTEZ91L71V4 ↗
- ChEMBLCHEMBL345524 ↗
- ChEMBLCHEMBL1201234 ↗
- ChEMBLCHEMBL1200996 ↗
Also known as
- mephentermine
- mephentermine
- mephentermine
- mephentermine
- mephentermine
- mephentermine
- mephentermine
- mephentermine
- mephentermine
- mephentermine
- mephentermine hemisulfate
- mephentermine sodium
- mephentermine sodium
- mephentermine sulfate
- mephentermine sulfate
- mephentermine sulfate
- mephentermine sulfate
- mephentermine sulphate
- mephine
- n-methylphentermine
- vialin
- wyamine
- wyamine
- wyamine sulfate
- wyamine sulfate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05706727 | Phase 3 | Mar 23, 2023 | KIST Medical College |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| KIST Medical College | Academic/Hospital | 1 | 1 | 1 | 2023 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| American Home Products | For profit | NDA | Dec 29, 1951 |
| Baxalta | For profit | MKTG | Dec 29, 1951 |
| Baxalta | For profit | NDA2 | Dec 29, 1951 |